Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Open and Key Laboratory of Hepatobiliary & Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities, Zhengzhou 450052, China; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou 450052, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Open and Key Laboratory of Hepatobiliary & Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities, Zhengzhou 450052, China; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou 450052, China.
Biomed Pharmacother. 2021 May;137:111390. doi: 10.1016/j.biopha.2021.111390. Epub 2021 Feb 16.
Long non-coding RNAs (lncRNAs) have more than 200 nucleotides and do not encode proteins. Based on numerous studies, lncRNAs have emerged as new and crucial regulators of biological function and have been implicated in the pathogenesis of a variety of diseases, especially cancers. Specific lncRNAs have been identified as novel molecular biomarkers for cancer diagnosis, prognosis, and treatment efficacy. Fetal-lethal non-coding developmental regulatory RNA (FENDRR, also known as FOXF1-AS1) is a novel lncRNA that is located at chr3q13.31 and has four exons and 3099 nucleotides, and its genomic site is located at chr3q13.31. FENDRR is abnormally expressed in a variety of cancers and is significantly associated with different clinical characteristics. In addition, FENDRR has shown potential as a biomarker for cancer diagnosis, prognosis, and treatment. In this review, we summarize the current understanding of FENDRR and its mechanistic role in cancer progression. We also discuss recent insights into the clinical significance of FENDRR for cancer diagnosis, prognosis, and treatment.
长链非编码 RNA（lncRNA）长度超过 200 个核苷酸，不编码蛋白质。基于大量研究，lncRNA 已成为生物功能的新的关键调控因子，并与多种疾病的发病机制有关，尤其是癌症。特定的 lncRNA 已被确定为癌症诊断、预后和治疗效果的新型分子生物标志物。胎致死性非编码发育调控 RNA（FENDRR，也称为 FOXF1-AS1）是一种新型的 lncRNA，位于 chr3q13.31，具有四个外显子和 3099 个核苷酸，其基因组位置位于 chr3q13.31。FENDRR 在多种癌症中异常表达，与不同的临床特征显著相关。此外，FENDRR 已显示出作为癌症诊断、预后和治疗标志物的潜力。在这篇综述中，我们总结了目前对 FENDRR 的认识及其在癌症进展中的机制作用。我们还讨论了 FENDRR 在癌症诊断、预后和治疗中的临床意义的最新见解。
